White House cue sparks surge in leucovorin prescriptions for autism
After a White House press conference suggested leucovorin could treat autism, a New England Journal of Medicine analysis found a 700% jump in pediatric prescriptions in 2025 (about 8 per 100,000 children by year’s end), with roughly 47,394 kids receiving 150,026 doses. Experts warn that the evidence for efficacy and safety is uncertain, caution against off-label use driven by government messaging, and note a 2026 retraction of the largest leucovorin–autism study, underscoring the need for rigorous data and better focus on services for autistic people.